Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04687956

Primary Surgical Prevention of Breast Cancer-related Lymphedema

Effect of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Primary Surgical Prevention of Breast Cancer-related Lymphedema

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Gangnam Severance Hospital · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

Lymphedema refers to edema caused by insufficient drainage of interstitial fluid through the lymphatic circulation system. It occurs mainly in the upper and lower extremities and causes chronic inflammation, and finally fibrous adipose tissue is replaced. In this study, the'LYMPHA' (Lymphatic microsurgical preventing healing approach) procedure, which connects lymphatic vessels drained from the arm to the side branches of the axillary vein, contributes to the prevention of lymphedema in patients undergoing axillary lymph node dissection for breast cancer. Investigator aim to help patients' quality of life by prospectively analyzing the effects and applying them to clinical practice, reducing the incidence of lymphedema.

Detailed description

Patients in the LYMPHA group undergo Axillary reverse mapping before the start of surgery, and after axillary lymph node resection, LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.

Conditions

Interventions

TypeNameDescription
PROCEDURELYMPHAAxillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
PROCEDUREcontrolIn the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.

Timeline

Start date
2021-02-01
Primary completion
2027-12-31
Completion
2027-12-31
First posted
2020-12-29
Last updated
2023-10-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04687956. Inclusion in this directory is not an endorsement.